Navigation Links
Inhaled nitric oxide therapy does not reduce death risk of infants

Premature infants with lung problem are often treated with inhaled nitric oxide// therapy. A recent study had brought out the fact that this therapy does not reduce the chances of death or further lung infections.

Researchers for the study are of opinion that premature babies who weigh less than 1.5kgs need not be given inhaled nitric oxide therapy unless they are the part of a study. Inhaled nitric oxide therapy is effective for treating lung infections in babies who are born after a full term pregnancy. This treatment makes the blood vessels in the body more effective in absorbing the oxygen for the metabolism.

Researchers who had conducted the study on 420 pre-term infants with lung infection found that there does not exist any significant difference between those infants who had received the therapy and those who were given a placebo. 60 % of the infants in the first group and 68% of infants in the placebo group had developed the serious lung infection of bronchopulmonary dysplasia. The death rate was also high in both groups, with 52% of the infants with inhaled nitric oxide and 48% of the infants with placebo failing to survive.

Reference: National Institutes of Health, Press release, July 2005
'"/>




Page: 1

Related medicine news :

1. Inhaled Steroids Safe & Effective for Children with Asthma
2. Inhaled Corticosteroids Found To Have No Significant Effect On COPD
3. The Effectiveness Of Inhaled Corticosteroids Studied
4. The Effectiveness Of Inhaled Corticosteroids Studied
5. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
6. HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy
7. Inhaled Insulin To Be Made Available in India
8. Inhaled Insulin Could Rock The Drug Market Soon
9. High Cost Forces NHS To Reject Inhaled Insulin
10. Inhaled Cyclosporine Results In Rejection Free Survival among Lung Transplant Patients
11. Inhaled Insulin: A New Modality for Management of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology: